Articles

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia

Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Department of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin
Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin
Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
Clinical Trials Office, Medical College of Wisconsin, Milwaukee, Wisconsin
Clinical Trials Office, Medical College of Wisconsin, Milwaukee, Wisconsin
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN; Division of Oncology Research, Mayo Clinic, Rochester, MN
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN; Division of Oncology Research, Mayo Clinic, Rochester, MN
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN; Division of Oncology Research, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Division of Hematology, Mayo Clinic, Rochester, Minnesota; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN; Division of Oncology Research, Mayo Clinic, Rochester, MN
Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
Vol. 109 No. 9 (2024): September, 2024 https://doi.org/10.3324/haematol.2024.285014